Chapter 850 Oregon Board of Naturopathic Medicine

850-040-0250

One-time Continuing Education Required Prior to Administering or Supervising the Administration of IV and Injectable Ketamine

(1) Four (4) hours of Board approved pharmacology education on prescribing Ketamine, including dosage and administration, clinical indications, and safety planning

(2) For administration for non-pain management purposes, two (2) hours of Board approved ethics education on Ketamine prescribing and treatment, including doctor-patient boundaries, enhanced consent, and therapy models.

Statutory/Other Authority: 685.106 Statutes/Other Implemented: 685.102 OFFICE OF THE SECRETARY OF STATE LAVONNE GRIFFIN-VALADE SECRETARY OF STATE

CHERYL MYERS DEPUTY SECRETARY OF STATE AND TRIBAL LIAISON



ARCHIVES DIVISION STEPHANIE CLARK DIRECTOR

800 SUMMER STREET NE SALEM, OR 97310 503-373-0701

NOTICE OF PROPOSED RULEMAKING INCLUDING STATEMENT OF NEED & FISCAL IMPACT

CHAPTER 850 OREGON BOARD OF NATUROPATHIC MEDICINE

FILING CAPTION: One-time CE Required Supervision and Administration of IV and Injectable Ketamine

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 02/12/2024 1:00 PM

The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.

A public rulemaking hearing may be requested in writing by 10 or more people, or by a group with 10 or more members, within 21 days following the publication of the Notice of Proposed Rulemaking in the Oregon Bulletin or 28 days from the date the Notice was sent to people on the agency mailing list, whichever is later. If sufficient hearing requests are received, the notice of the date and time of the rulemaking hearing must be published in the Oregon Bulletin at least 14 days before the hearing.

CONTACT: Mary-Beth Baptista 971-673-0193 marybeth.baptista@obnm.oregon.gov 800 NE Oregon Street, Ste 407 Portland,OR 97232 Filed By: Mary-Beth Baptista Rules Coordinator

NEED FOR THE RULE(S)

Clarifies One-time Continuing Education Required Prior to Administering or Supervising the Administration of IV and Injectable Ketamine, moves to division 40

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE

OBNM website - Board public meeting minutes

STATEMENT IDENTIFYING HOW ADOPTION OF RULE(S) WILL AFFECT RACIAL EQUITY IN THIS STATE

Rule will not affect racial equity in the state

FISCAL AND ECONOMIC IMPACT:

Rule does not have a fiscal or economic impact

COST OF COMPLIANCE:

(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).

Rule does not have a cost of compliance

DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

Small businesses were not affected and not involved

FILED

12/27/2023 4:00 PM ARCHIVES DIVISION SECRETARY OF STATE

WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?

Discussion at multiple public board meetings

ADOPT: 850-040-0250

RULE SUMMARY: Clarifies and moves to division 40 One-time Continuing Education Required Prior to Administering or Supervising the Administration of IV and Injectable Ketamine

CHANGES TO RULE:

850-040-0250

<u>One-time Continuing Education Required Prior to Administering or Supervising the Administration of IV and</u> <u>Injectable Ketamine</u>

(1) Four (4) hours of Board approved pharmacology education on prescribing Ketamine, including dosage and administration, clinical indications, and safety planning¶

(2) For administration for non-pain management purposes, two (2) hours of Board approved ethics education on Ketamine prescribing and treatment, including doctor-patient boundaries, enhanced consent, and therapy models. Statutory/Other Authority: 685.106

Statutes/Other Implemented: 685.102

OFFICE OF THE SECRETARY OF STATE LAVONNE GRIFFIN-VALADE SECRETARY OF STATE

CHERYL MYERS DEPUTY SECRETARY OF STATE AND TRIBAL LIAISON



CHAPTER 850 OREGON BOARD OF NATUROPATHIC MEDICINE

FILING CAPTION: Updated and clarified version of rule moved to Division 40 CE

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 02/12/2024 1:00 PM

The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.

A public rulemaking hearing may be requested in writing by 10 or more people, or by a group with 10 or more members, within 21 days following the publication of the Notice of Proposed Rulemaking in the Oregon Bulletin or 28 days from the date the Notice was sent to people on the agency mailing list, whichever is later. If sufficient hearing requests are received, the notice of the date and time of the rulemaking hearing must be published in the Oregon Bulletin at least 14 days before the hearing.

CONTACT: Mary-Beth Baptista 971-673-0193 marybeth.baptista@obnm.oregon.gov 800 NE Oregon Street, Ste 407 Portland, OR 97232 Filed By: Mary-Beth Baptista Rules Coordinator

NEED FOR THE RULE(S)

Updated and clarified version of rule moved to Division 40 CE

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE

Board public meeting minutes - OBNM website

STATEMENT IDENTIFYING HOW ADOPTION OF RULE(S) WILL AFFECT RACIAL EQUITY IN THIS STATE

Rule will not affect racial equity in Oregon

FISCAL AND ECONOMIC IMPACT:

No fiscal or economic impact

COST OF COMPLIANCE:

(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).

Rule has no cost of compliance

DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

Small businesses are not affected and not involved

WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?



ARCHIVES DIVISION STEPHANIE CLARK DIRECTOR

800 SUMMER STREET NE SALEM, OR 97310 503-373-0701



REPEAL: 850-060-0210

RULE SUMMARY: Repeals Education and Reporting Requirements for Ketamine Therapy - Updated and clarified version of rule moved to Division 40 CE

CHANGES TO RULE:

850-060-0210

Education and Reporting Requirements for Ketamine Therapy

(1) Prior to prescribing non-topical ketamine; a Licensee must provide the Board proof of completion of four (4) hours of Board approved pharmacology education on prescribing Ketamine, including dosage and administration, clinical indications, and safety planning¶

(2) Prior to prescribing non-topical ketamine, unless prescribing ketamine for pain management only, a Licensee must provide the Board proof of completion of two (2) hours of Board approved ethics education on Ketamine prescribing and treatment, including doctor-patient boundaries, enhanced consent, and therapy models.
 (3) IV and Injectable Ketamine must be administered and supervised for the duration of the treatment by a Licensee who has completed the required training in Section 1 and 2.

(4) Licensees may submit to the Board proof of approved education required in Section 1 and 2, earned before December 31, 2022, for approval for compliance with this rule.

Statutory/Other Authority: ORS 685.106, ORS 685.102

Statutes/Other Implemented: ORS 685.106, ORS 685.102